Compare American Tower Corp (AMT) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
American Tower Corp vs Regeneron Pharmaceuticals Inc — how do they compare? American Tower Corp trades at $169.8 (market cap $78.80B), while Regeneron Pharmaceuticals Inc trades at $796.38 (market cap $83.19B). The key difference: American Tower Corp and Regeneron Pharmaceuticals Inc are close in size by market cap, and American Tower Corp pays the higher dividend (4.13%). Which is the better fit depends on your goals.
| AMT | REGN | |
|---|---|---|
Market Cap | $78.80B | $83.19B |
Sector | Real Estate | Health |
52-Week High | $211.88 | $812.27 |
52-Week Low | $162.11 | $555.51 |
Enterprise Value | $122.32B | $77.90B |
Dividend Yield | 4.13% | 0.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
American Tower (AMT) trades at $172.54, up 0.78% on the day, with a neutral technical signal and strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $1.86 exceeding the $1.57 forecast. Revenue for 2025 reached $10.64 billion, with a robust net income margin of 26.81%. Analyst sentiment is overwhelmingly positive, with 39 of 49 analysts rating it a Buy and a consensus price target of $206.17, implying significant upside. Recent news highlights insider selling and upbeat analyst coverage.
The outlook for AMT is favorable, driven by resilient telecom demand, 5G/6G expansion, and double-digit growth in its data center segment. Key risks include sensitivity to interest rates, Dish Network churn impacts, and high debt levels. With strong cash flow from operations and a bullish analyst consensus, the stock presents a compelling opportunity for growth-oriented investors, though macroeconomic factors warrant monitoring.
Regeneron Pharmaceuticals (REGN) trades at $784.36, up 1.59% today, with a bullish technical signal from moving averages but overbought RSI readings. The company shows strong profitability with a net income margin of 27.86% and has beaten EPS estimates in recent quarters. However, multiple class-action lawsuits filed in August 2026 allege inadequate clinical-trial risk disclosures, creating investor uncertainty amid solid financial performance.
Outlook remains supported by earnings momentum and analyst buy ratings, but legal risks and high valuation multiples pose near-term headwinds. Investment opportunity hinges on legal resolution and sustained drug pipeline success, while risks include trial setbacks and regulatory scrutiny.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About American Tower Corp
American Tower owns and operates more than 220,000 cell towers throughout the U.S., Asia, Latin America, Europe, and Africa. It also owns and/or operates 25 data centers in eight U.S. markets after acquiring CoreSite. On its towers, the company has a very concentrated customer base, with most revenue in each market being generated by just the top few mobile carriers. The company operates more than 40,000 towers in the U.S., which accounted for more than half of its total revenue in 2021. Outside the U.S., American Tower's greatest presence is in India and Brazil, where it operates roughly 75,000 and 19,000 towers, respectively. American Tower operates as a real estate investment trust.
Read more on AMT →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
